THE activity of aureomycin includes a wider variety of the known causative agents of pneumonia than that of any of the earlier effective chemicals or antibiotics1. Clinical trials were, therefore, undertaken of the use of aureomycin in all types of nontuberculous pneumonia and other severe acute infections of the respiratory tract that were available for study. In separate communications, we have presented the results of aureomycin treatment in cases of primary atypical (virus) pneumonia,2 in cases of pneumococcic pneumonias3 and in a variety of other cases which includes influenza and other severe acute infections of the respiratory tract and pneumonias in which a likely causative bacterial agent could not be identified.4 In this paper are presented the results of aureomycin therapy in cases of the nonpneumococcic and nontuberculous bacterial infections of the lungs.
MATERIALS AND METHODS
Selection of Cases.
—Two groups of cases were studied and
COLLINS HS, GOCKE TM, FINLAND M. AUREOMYCIN THERAPY OF NONPNEUMOCOCCIC AND NONTUBERCULOUS BACTERIAL PULMONARY INFECTIONS. Arch Intern Med (Chic). 1949;84(6):875–890. doi:10.1001/archinte.1949.00230060032003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: